Merial acquires Legend, Marquis equine products from Bayer
Products used to treat osteoarthritis, EPM in horses.
Merial recently acquired Legend (hyaluronate sodium) and Marquis (ponazuril) from Bayer HealthCare, expanding its portfolio in performance horse healthcare, the company announced.
Legend is an FDA-approved product labeled for both intra-articular and intravenous injection and indicated in the treatment of joint dysfunction associated with equine osteoarthritis. In studies, clinical improvement was judged to be excellent or good in 90 percent or more of cases treated intravenously or intra-articularly with Legend.
Marquis is an FDA-approved treatment for equine protozoal myeloencephalitis (EPM), a neurological disease caused by Sarcocystis neurona, a parasite that invades the brain and spinal cord. If left untreated, it can lead to permanent damage to the central nervous system or death. When used as directed, Marquis crosses the blood-brain barrier to kill S. neurona, stopping the parasite from inflicting further damage to the central nervous system.
For more information about these products, visit equinelegend.com or merialmarquis.com.
